Lessons from Seven Decades of Antituberculosis Drug Discovery

被引:0
作者
Barry, Clifton E. [1 ]
机构
[1] NIAID, TB Res Sect, LCID, NIH, Bethesda, MD 20892 USA
关键词
Tuberculosis; drug development; streptomycin; rifampicin; isoniazid; linezolid; nitroimidazoles; diarylquinoline; benzothiazinone; MYCOBACTERIUM-TUBERCULOSIS; IN-VITRO; RESISTANT; ANTIBIOTICS; IDENTIFICATION; EPIDEMIOLOGY; STREPTOMYCIN; ACTIVATION; PNU-100480; CANDIDATE;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Despite massive global efforts tuberculosis rates continue to climb and drug-resistance rates are rising to alarming levels. Discovering new agents for treating this bacterial pathogen poses unique challenges, but these challenges have been faced throughout the entire modern history of research into anti-infectives. This review looks back at every decade since the 1940s and summarizes the most important drugs developed during each decade highlighting the lessons learned during these successful medicinal chemistry programs. Looking forward we must accelerate the integration of these past lessons with the impressive advances that have been made in the basic understanding of the biology of this disease.
引用
收藏
页码:1216 / 1225
页数:10
相关论文
共 74 条
[1]   A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis [J].
Andries, K ;
Verhasselt, P ;
Guillemont, J ;
Göhlmann, HWH ;
Neefs, JM ;
Winkler, H ;
Van Gestel, J ;
Timmerman, P ;
Zhu, M ;
Lee, E ;
Williams, P ;
de Chaffoy, D ;
Huitric, E ;
Hoffner, S ;
Cambau, E ;
Truffot-Pernot, C ;
Lounis, N ;
Jarlier, V .
SCIENCE, 2005, 307 (5707) :223-227
[2]  
[Anonymous], 1975, Lancet, V1, P119
[3]  
[Anonymous], 1974, Lancet, V2, P237
[4]  
ANSCHEL R, 1965, Wien Med Wochenschr, V115, P197
[5]   Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid [J].
Argyrou, A ;
Vetting, MW ;
Aladegbami, B ;
Blanchard, JS .
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2006, 13 (05) :408-413
[6]   INVITRO AND INVIVO ACTIVITIES OF THE NITROIMIDAZOLE CGI-17341 AGAINST MYCOBACTERIUM-TUBERCULOSIS [J].
ASHTEKAR, DR ;
COSTAPERIRA, R ;
NAGRAJAN, K ;
VISHVANATHAN, N ;
BHATT, AD ;
RITTEL, W .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (02) :183-186
[7]   Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis [J].
Aziz, Mohamed Abdel ;
Wright, Abigail ;
Laszlo, Adalbert ;
De Muynck, Aime ;
Portaels, Francois ;
Van Deun, Armand ;
Wells, Charles ;
Nunn, Paul ;
Blanc, Leopold ;
Raviglione, Mario .
LANCET, 2006, 368 (9553) :2142-2154
[8]   Mechanisms of isoniazid resistance in Mycobacterium tuberculosis [J].
Barry, CE ;
Slayden, RA ;
Mludli, K .
DRUG RESISTANCE UPDATES, 1998, 1 (02) :128-134
[9]   Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis [J].
Barry, CE ;
Boshoff, HIM ;
Dowd, CS .
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (26) :3239-3262
[10]   Unorthodox Approach to the Development of a New Antituberculosis Therapy [J].
Barry, Clifton E., III .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (23) :2466-2467